Clinical Trial Update: Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)

View source ↗

Summary

Post-market surveillance results for OZURDEX (dexamethasone intravitreal implant) in branch retinal vein occlusion and central retinal vein occlusion with macul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Retinal Vein Occlusion
• Central Retinal Vein Occlusion
• Macular Edema

Drugs mentioned

• Ozurdex (dexamethasone intravitreal implant)

Snippet

Sponsor: Allergan | Conditions: Retinal Vein Occlusion, Macular Edema | Status: COMPLETED | Results posted: 2015-02-10